Refine your search
Collections
Journals
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Bhalerao, Roshani
- Synthesis and Evaluation of Antidiabetic Activity of Few 5-(4-(5-Substitutedphenyl)-1,3,4-Oxadiazlole-2-Yl) Methoxy)Benzylidene) Thiazolidine 2,4-Dione Derivatives
Abstract Views :459 |
PDF Views:0
Authors
Affiliations
1 MET’S Institute of Pharmacy, Bhujbal Knowledge City, Adgaon, Nashik-422003, Savitribai Phule Pune University, IN
1 MET’S Institute of Pharmacy, Bhujbal Knowledge City, Adgaon, Nashik-422003, Savitribai Phule Pune University, IN
Source
Asian Journal of Pharmaceutical Research, Vol 7, No 4 (2017), Pagination: 261-264Abstract
The aim of study was to synthesize a new series of Thiazolidinedione. Thiazolidinedione or glitziness forms a significant class of drug which exhibit biological activities ranging from antidiabetic, antiinflamatory, antibacterial, antifungal, antiviral, and anti-cancer. In the present study reported a systematic synthesis of thiazolidinedione. A new series of 2,4-thiazolidinedione based derivative have been synthesize by condensation of. The structure of these compounds were establish by IR and 1H NMR. These new compound (C1-C4) were evaluated for their antidiabetic activity on albino rat. Most of compound shows significant antidiabetic activity when compare with standard drug metformin.Keywords
Diabetic Mellitus, Thiazolidinedione, Antidiabetic Activity.
References
- Mohd Javed Naim, Ozair Alam and Farah Nawaz RECENT TARGET BASED DISCOVERY OF ANTI-DIABETIC AGENTS India International Journal of Pharmaceutical Sciences and Research.
- Mohd Imran, deepanjali, suroor ahamd khan. Recent thiazolidinedione antidiabetic. Journal of scientific and industrial research vol 1 66 2007 February pp 99- 109.
- Prashant B Mane, Rishikesh V Antre and Rajesh J Oswal. Antidiabetic Drugs: An Overview. INTERNATIONAL JOURNAL OF PHARMACEUTICAL AND CHEMICAL SCIENCES.
- Swapana D, Shivagami B, Manasa K. Synthesis ans evaluation of novel thiazolidinedione derivative of antidiabetic activity. International Research Journal of Pharmacy.
- Rekha. S, Shantaram. U. SYNTHESIS AND EVALUATION OF NOVEL THIAZOLIDINEDIONES FOR ANTI DIABETIC ACTIVITY. International Journal of Pharmacy and Pharmaceutical Sciences ISSN- 0975-1491 Vol 3, Suppl 5, 2011
- Shashikant R. Pattana, Prajact Kekareb, Ashwini Patilc, Ana Nikaljec, BS Kitturd the Synthesis of Novel 2,4-ThiazolidinedioneDerivatives with Antidiabetic Activity Kitturd Iranian Journal of Pharmaceutical Sciences Autumn 2009: 5(4): 225-230
- Daniel J. Toft a, Miles Fuller a, Matthew Schipma b, Feng Chena, Vincent L. Cryns c αB-crystallin and HspB2 deficiency is protective from diet-induced glucose intolerance: www.elsevier.com
- Donald McClain, Animal Models of Diabetic Complications Consortium Intraperitoneal Glucose Tolerance Testing (IPGTT) Version: 1.0
- Amy R. Blair, Nadia Deluca, Barbara C. Fam, and Joseph Proietto Am. Evaluating the glucose tolerance test in mice Sofianos And rikopoulos. J Physiol Endocrinol Metab 295: E1323–E1332, 2008
- Insulin Therapies:Current and Future Trends
Abstract Views :519 |
PDF Views:0
Authors
Affiliations
1 MET’S Institute of Pharmacy, Bhujbal Knowledge City, Adgaon, Nashik-422003, Savitribai Phule Pune University, IN
1 MET’S Institute of Pharmacy, Bhujbal Knowledge City, Adgaon, Nashik-422003, Savitribai Phule Pune University, IN
Source
Asian Journal of Research in Pharmaceutical Sciences, Vol 7, No 4 (2017), Pagination: 189-196Abstract
Many patients with advanced type 2 diabetes mellitus (T2DM) and all patients with T1DM require insulin to keep blood glucose levels in the target range. The most common route of insulin administration is subcutaneous insulin injections. There are many ways to deliver insulin subcutaneously such as vials and syringes, insulin pens, and insulin pumps. Though subcutaneous insulin delivery is the standard route of insulin administration, it is associated with injection pain, needle phobia, lipodystrophy, noncompliance and peripheral hyperinsulinemia. Therefore, the need exists for delivering insulin in a minimally invasive or noninvasive and in most physiological way. Inhaled insulin was the first approved noninvasive and alternative way to deliver insulin, but it has been withdrawn from the market. Technologies are being explored to make the noninvasive delivery of insulin possible. Some of the routes of insulin administration that are under investigation are oral, buccal, nasal, peritoneal and transdermal. This review article focuses on the various insulin delivery techniques. This article has focused on different possible routes of insulin administration with its advantages and limitation and possible scope for the new drug development.Keywords
Diabetes Mellitus, Inhaled Insulin, Insulin Delivery, Oral Insulin, Technology, Closed-Loop System, Artificial Pancreas.References
- Garg, S. K., et al. (2013). Use of non-insulin therapies for type 1 diabetes, Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA.
- Group, U. P. D. S. (1995). "UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease." Diabetes 44(11): 1249-1258.
- Yaturu, S. (2013). "Insulin therapies: current and future trends at dawn." World J Diabetes 4(1): 1-7.
- Rima B. Shah1, M. P., David M. Maahs, Viral N. Shah (2016). "Insulin delivery methods: Past, present and future " International Journal of Pharmaceutical Investigation 6(1).
- Fry, A. (2012). "Insulin Delivery Device Technology 2012: where are we after 90 years?" Journal of Diabetes Science and Technology 6(4): 947-953.
- Penfornis, A., et al. (2011). "Evolution of devices in diabetes management." Diabetes Technology & Therapeutics13(S1): S-93-S-102.
- Shah, R. B., et al. (2016). "Insulin delivery methods: Past, present and future." International Journal of Pharmaceutical Investigation 6(1): 1.
- Cohen, O., et al. (2009). "Improved glycemic control through continuous glucose sensor-augmented insulin pump therapy: prospective results from a community and academic practice patient registry." Journal of Diabetes Science and Technology 3(4): 804-811.
- Burdick, P., et al. (2009). "Use of a subcutaneous inj ction port to improve glycemic control in children with type 1 diabetes." Pediatric Diabetes10(2): 116-119.
- Shah, V. N., et al. (2014). Closed-loop system in the management of diabetes: past, present, and future, Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA.